Assessment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML)
Not Applicable
Active, not recruiting
- Conditions
- Chronic Myeloid Leukaemia (CML)Cancer - Leukaemia - Chronic leukaemia
- Registration Number
- ACTRN12610000055000
- Lead Sponsor
- Australasian Leukaemia and Lymphoma Group (ALLG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Patients of any age
Currently recieving Tyrosine Kinase Inhibitor(TKI)
Patients with Philadelphia Positive or Breakpoint Cluster Region (BCR) V-abl Abelson murine leukaemia viral oncogene homolog1 (ABL) confirmed CML.
Patients in any phase of CML including those with relapsed CML following allogeneic stem cell transplantation
Patients who can provide written informed consent. Minors must have parental/legal guardian consent and assent where required
Exclusion Criteria
If in the investigator's opinion the patient is unlikely candidate for follow-up information due to unavailability.
Previous enrolment to the same registry.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the range and frequency of next-line therapies. The clincian will complete data into the case report form and submit to trial coordinating centre.[6month data collection.<br> 12month data review annually for five years.]
- Secondary Outcome Measures
Name Time Method progression free survival by routine blood tests performed as standard by the clinician[3 or 6 monthly depending on patient and clinician. it is an observational study, so these timepoints may change according to the treating clinician and patient.];overall survival, measured at visit to clinician.[at each clinician visit, 6monthly minimum.]